Kamada KMDA
NASDAQ KMDA
$8.21 -0.08 (-0.97%)
As of: Sep 9, 2026 · 3:59 PM EDT

Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026)

Kamada's (KMDA) quarterly Total Non-Current Liabilities came in at $64.4 million in Q2 2026, up 3.2% on a YoY basis from $62.4 million in Q2 2025, and up 0.92% quarter-over-quarter from $63.9 million in Q1 2026.

Analysis

Kamada (KMDA) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Total Non-Current Liabilities for 13 consecutive years, with $64.4 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Total Non-Current Liabilities rose 3.2% year-over-year to $64.4 million; the trailing twelve-month figure through Jun 2026 stood at $64.4 million (up 3.2% YoY), and the FY2025 full-year result was $62.2 million, down 1.82% from the prior year.
  • Total Non-Current Liabilities improved to $64.4 million in Q2 2026 per KMDA's latest filing, from $63.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $85.7 million in Q1 2022 and bottomed at -$6.3 million in Q4 2022.
  • Historically, Total Non-Current Liabilities has averaged $59.6 million across 5 years, with a median of $63.6 million in 2024.
  • The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities plunged 530.38% in 2022, then soared 6569.59% in 2024.
  • Over 5 years, Total Non-Current Liabilities stood at -$6.3 million in 2022, then soared by 84.36% to -$980000.0 in 2023, then jumped by 6569.59% to $63.4 million in 2024, then retreated by 1.82% to $62.2 million in 2025, then advanced by 3.53% to $64.4 million in 2026.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $64.4 million, $63.9 million, and $62.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 211.39 Bn 197.40 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 181.14 Bn 177.96 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 132.24 Bn 124.39 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 82.91 Bn 74.91 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 61.55 Bn 56.36 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.39 Bn 49.25 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 34.43 Bn 31.12 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.18 Bn 29.89 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 30.11 Bn 30.11 Bn 1.16 Mn 378.37 Mn
10 Kamada 472.70 Mn 402.57 Mn 22.47 Mn 64.45 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 64.45 Mn
Mar 31, 2026 63.86 Mn
Dec 31, 2025 62.25 Mn
Sep 30, 2025 64.14 Mn
Jun 30, 2025 62.45 Mn
Mar 31, 2025 66.10 Mn
Dec 31, 2024 63.40 Mn
Sep 30, 2024 61.94 Mn
Jun 30, 2024 58.99 Mn
Mar 31, 2024 59.49 Mn
Dec 31, 2023 -980,000.00
Sep 30, 2023 61.39 Mn
Jun 30, 2023 71.81 Mn
Mar 31, 2023 72.71 Mn
Dec 31, 2022 -6.27 Mn
Sep 30, 2022 77.94 Mn
Jun 30, 2022 82.88 Mn
Mar 31, 2022 85.72 Mn
Dec 31, 2021 -994,000.00
Sep 30, 2021 8.33 Mn